1-4 of 4
Deepa Rangachari
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes

Catherine B. Meador, Subba R. Digumarthy, Beow Y. Yeap, Yin P. Hung, Mari Mino-Kenudson, Anna F. Farago, Rebecca S. Heist, J. Paul Marcoux, Deepa Rangachari, David A. Barbie, Zofia Piotrowska
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 25–34.
https://doi.org/10.1158/1078-0432.CCR-24-2350
Published: 06 January 2025
View article titled, Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes
Open the PDF for Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes in another window
Includes: Supplementary data
Journal Articles

Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

Alissa J. Cooper, Yoshihisa Kobayashi, Dewey Kim, Sarah E. Clifford, Sasha Kravets, Suzanne E. Dahlberg, Emily S. Chambers, Jiaqi Li, Deepa Rangachari, Tom Nguyen, Daniel B. Costa, Michael S. Rabin, Nikhil Wagle, Lynette M. Sholl, Pasi A Jänne, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15): 4072–4079.
https://doi.org/10.1158/1078-0432.CCR-20-0397
Published: 03 August 2020
View article titled, Identification of a RAS-activating <em>TMEM87A–RASGRF1</em> Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer
Open the PDF for Identification of a RAS-activating <em>TMEM87A–RASGRF1</em> Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2277.
https://doi.org/10.1158/1078-0432.CCR-20-0939
Published: 01 May 2020
View article titled, Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Open the PDF for Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas in another window
Journal Articles

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6548–6555.
https://doi.org/10.1158/1078-0432.CCR-18-1541
Published: 13 December 2018
View article titled, EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Open the PDF for EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas in another window
Includes: Supplementary data